A response to Al et al. Trials 2023;24:233

In their recent paper, Al and colleagues (Trials 2023;24:233) argue that manipulation of the methods of recruitment using well-known techniques in order to increase enrollment can be ethically acceptable. This brief response challenges that notion as an affront to voluntariness and a devolution of t...

Descripción completa

Detalles Bibliográficos
Autor principal: Merz, Jon F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424340/
https://www.ncbi.nlm.nih.gov/pubmed/37574550
http://dx.doi.org/10.1186/s13063-023-07574-9
_version_ 1785089649628151808
author Merz, Jon F.
author_facet Merz, Jon F.
author_sort Merz, Jon F.
collection PubMed
description In their recent paper, Al and colleagues (Trials 2023;24:233) argue that manipulation of the methods of recruitment using well-known techniques in order to increase enrollment can be ethically acceptable. This brief response challenges that notion as an affront to voluntariness and a devolution of the ethics of human subjects research to the “ethics” of the marketplace.
format Online
Article
Text
id pubmed-10424340
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104243402023-08-15 A response to Al et al. Trials 2023;24:233 Merz, Jon F. Trials Letter In their recent paper, Al and colleagues (Trials 2023;24:233) argue that manipulation of the methods of recruitment using well-known techniques in order to increase enrollment can be ethically acceptable. This brief response challenges that notion as an affront to voluntariness and a devolution of the ethics of human subjects research to the “ethics” of the marketplace. BioMed Central 2023-08-13 /pmc/articles/PMC10424340/ /pubmed/37574550 http://dx.doi.org/10.1186/s13063-023-07574-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter
Merz, Jon F.
A response to Al et al. Trials 2023;24:233
title A response to Al et al. Trials 2023;24:233
title_full A response to Al et al. Trials 2023;24:233
title_fullStr A response to Al et al. Trials 2023;24:233
title_full_unstemmed A response to Al et al. Trials 2023;24:233
title_short A response to Al et al. Trials 2023;24:233
title_sort response to al et al. trials 2023;24:233
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424340/
https://www.ncbi.nlm.nih.gov/pubmed/37574550
http://dx.doi.org/10.1186/s13063-023-07574-9
work_keys_str_mv AT merzjonf aresponsetoaletaltrials202324233
AT merzjonf responsetoaletaltrials202324233

Ejemplares similares